Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pBabepuro-myc-ER Citations (15)

Originally described in: Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.
Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, El-Deiry WS Mol Cell Biol. 2004 Oct . 24(19):8541-55.
PubMed Journal

Articles Citing pBabepuro-myc-ER

Articles
Myc regulates the transcription of the PRC2 gene to control the expression of developmental genes in embryonic stem cells. Neri F, Zippo A, Krepelova A, Cherubini A, Rocchigiani M, Oliviero S. Mol Cell Biol. 2012 Feb;32(4):840-51. doi: 10.1128/MCB.06148-11. Epub 2011 Dec 19. PubMed
A c-Myc-MicroRNA functional feedback loop affects hepatocarcinogenesis. Han H, Sun D, Li W, Shen H, Zhu Y, Li C, Chen Y, Lu L, Li W, Zhang J, Tian Y, Li Y. Hepatology. 2013 Jun;57(6):2378-89. doi: 10.1002/hep.26302. PubMed
MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism. Akita H, Marquardt JU, Durkin ME, Kitade M, Seo D, Conner EA, Andersen JB, Factor VM, Thorgeirsson SS. Cancer Res. 2014 Oct 15;74(20):5903-13. doi: 10.1158/0008-5472.CAN-14-0527. Epub 2014 Sep 4. PubMed
Aurora kinase A mediates c-Myc's oncogenic effects in hepatocellular carcinoma. Lu L, Han H, Tian Y, Li W, Zhang J, Feng M, Li Y. Mol Carcinog. 2014 Oct 4. doi: 10.1002/mc.22223. PubMed
c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias. Muvarak N, Kelley S, Robert C, Baer MR, Perrotti D, Gambacorti-Passerini C, Civin C, Scheibner K, Rassool FV. Mol Cancer Res. 2015 Apr;13(4):699-712. doi: 10.1158/1541-7786.MCR-14-0422. Epub 2015 Mar 31. PubMed
c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer. Maina PK, Shao P, Liu Q, Fazli L, Tyler S, Nasir M, Dong X, Qi HH. Oncotarget. 2016 Nov 15;7(46):75585-75602. doi: 10.18632/oncotarget.12310. PubMed
MRE11 Promotes Tumorigenesis by Facilitating Resistance to Oncogene-Induced Replication Stress. Spehalski E, Capper KM, Smith CJ, Morgan MJ, Dinkelmann M, Buis J, Sekiguchi JM, Ferguson DO. Cancer Res. 2017 Oct 1;77(19):5327-5338. doi: 10.1158/0008-5472.CAN-17-1355. Epub 2017 Aug 17. PubMed
Poleta, a Y-family translesion synthesis polymerase, promotes cellular tolerance of Myc-induced replication stress. Kurashima K, Sekimoto T, Oda T, Kawabata T, Hanaoka F, Yamashita T. J Cell Sci. 2018 Jun 25;131(12). pii: jcs.212183. doi: 10.1242/jcs.212183. PubMed
CBFbeta-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia. Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, O'Hagan K, Ou J, Muller-Tidow C, Wolfe SA, Zhu LJ, Dekker J, Bushweller JH, Castilla LH. Cell. 2018 Jun 28;174(1):172-186.e21. doi: 10.1016/j.cell.2018.05.048. PubMed
Evidence that the human cell cycle is a series of uncoupled, memoryless phases. Chao HX, Fakhreddin RI, Shimerov HK, Kedziora KM, Kumar RJ, Perez J, Limas JC, Grant GD, Cook JG, Gupta GP, Purvis JE. Mol Syst Biol. 2019 Mar 18;15(3):e8604. doi: 10.15252/msb.20188604. PubMed
Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. Lankes K, Hassan Z, Doffo MJ, Schneeweis C, Lier S, Ollinger R, Rad R, Kramer OH, Keller U, Saur D, Reichert M, Schneider G, Wirth M. Mol Oncol. 2020 Dec;14(12):3048-3064. doi: 10.1002/1878-0261.12835. Epub 2020 Nov 8. PubMed
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3beta-Mediated c-Myc and Pim-1 Proteasomal Degradation. Scarpa M, Singh P, Bailey CM, Lee JK, Kapoor S, Lapidus RG, Niyongere S, Sangodkar J, Wang Y, Perrotti D, Narla G, Baer MR. Mol Cancer Ther. 2021 Apr;20(4):676-690. doi: 10.1158/1535-7163.MCT-20-0663. Epub 2021 Feb 10. PubMed
Immortalized striatal precursor neurons from Huntington's disease patient-derived iPS cells as a platform for target identification and screening for experimental therapeutics. Akimov SS, Jiang M, Kedaigle AJ, Arbez N, Marque LO, Eddings CR, Ranum PT, Whelan E, Tang A, Wang R, DeVine LR, Talbot CC, Cole RN, Ratovitski T, Davidson BL, Fraenkel E, Ross CA. Hum Mol Genet. 2021 Jul 22. pii: 6325571. doi: 10.1093/hmg/ddab200. PubMed
Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication. Scarpa M, Kapoor S, Tvedte ES, Doshi KA, Zou YS, Singh P, Lee JK, Chatterjee A, Ali MKM, Bromley RE, Hotopp JCD, Rassool FV, Baer MR. Oncotarget. 2021 Aug 31;12(18):1763-1779. doi: 10.18632/oncotarget.28042. eCollection 2021 Aug 31. PubMed
Elevating SOX2 Downregulates MYC through a SOX2:MYC Signaling Axis and Induces a Slowly Cycling Proliferative State in Human Tumor Cells. Metz EP, Wilder PJ, Popay TM, Wang J, Liu Q, Kalluchi A, Rowley MJ, Tansey WP, Rizzino A. Cancers (Basel). 2022 Apr 12;14(8). pii: cancers14081946. doi: 10.3390/cancers14081946. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.